SCHEMBL16185133

SCHEMBL16185133

CNc1nc(-c2ccnnc2)nc2c(OC)cc(-c3cccc(F)c3)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 7/20 0.40
▸ KIT P10721 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ AURKA O14965 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ FYN P06241 2/20 0.37
▸ MAP4K4 O95819 1/20 0.36
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185163 0.92 S1PR1 (0.38) ABCG2KITPSEN1PSEN2APH1B
SCHEMBL14474195 0.90 PSEN1 (0.41) ABCG2KITPDGFRBPDGFRAPSEN1
SCHEMBL16185139 0.89 GRM5 (0.47) ABCG2KITPDGFRBPDGFRAMAP4K4
SCHEMBL16183564 0.89 CYP1A2 (0.48) ABCG2KITPDGFRBPDGFRACYP1A2
SCHEMBL16185135 0.86 KIT (0.44) ABCG2KITPDGFRBPDGFRAAURKA
SCHEMBL16185132 0.85 KIT (0.43) ABCG2KITPDGFRBPDGFRAAURKA
SCHEMBL14474670 0.85 PSEN1 (0.42) ABCG2KITPSEN1PSEN2APH1B
SCHEMBL16185153 0.85 PSEN1 (0.40) ABCG2KITPSEN1PSEN2APH1B
SCHEMBL14474688 0.84 LMNA (0.39) ABCG2PSEN1PSEN2APH1BNCSTN
SCHEMBL16185125 0.84 CYP1A2 (0.42) ABCG2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB ABCG2 1597/4885KIT 3161/4885PDGFRB 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback